09/900,147

WEST

Freeform Search

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: L2 and e2f protein

Display: 15 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences | Cases

Search History

DATE: Monday, December 16, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L3	L2 and e2f protein	12	L3
L2	dp protein	28	L2
L1	dp-1	231	L1

END OF SEARCH HISTORY

L3: Entry 1 of 12 File: USPT Sep 10, 2002

US-PAT-NO: 6448376
DOCUMENT-IDENTIFIER: US 6448376 B1

TITLE: Transcription factor-E2F-5

DATE-ISSUED: September 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
La Thangue; Nicholas B.	London			GB
Bernards; Rene	Amsterdam			NL
Hijmans; Eleonore M.	Amsterdam			NL

US-CL-CURRENT: 530/350; 435/4, 530/300, 530/324

CLAIMS:

What is claimed is:

1. An isolated E2F-5 polypeptide selected from the group of: the polypeptide comprising SEQ ID NO:2; the polypeptide comprising SEQ ID NO:4; a polypeptide comprising a fragment of SEQ ID NO:2 of at least 60 amino acids, said fragment being capable of forming a transactivation complex with a DP protein; and a polypeptide comprising a fragment of SEQ ID NO:4 of at least 60 amino acids, said fragment being capable of forming a transactivation complex with a DP protein.

2. An isolated polypeptide comprising SEQ ID NO:2.

3. An isolated polypeptide comprising SEQ ID NO:4.

4. An Isolated polypeptide comprising a fragment of at least 60 amino acids of the isolated polypeptide of claim 2 or 3 said fragment being capable of forming a transactivation complex with a DP protein.

5. The isolated polypeptide of claim 1 that is detectably labeled.

6. The isolated polypeptide of claim 1 fixed to a solid phase.

7. A composition comprising the polypeptide according to claim 1 together with a carrier or diluent.

8. A screening assay for identifying an inhibitor of E2F-5/DP complex formation, which assay comprises: bringing into contact: (i) a DP polypeptide, said DP polypeptide being a component of an E2F transcription factor; (ii) the E2F-5 polypeptide of claim 1; and (iii) a putative inhibitor; under conditions in which the components (i) and (ii) in the absence of said putative inhibitor are able to form a complex; and determining the extent to which, if any, the presence of said putative inhibitor is able to disrupt the formation of the complex.

9. The screening assay of claim 8 wherein said determining is made by examining the ability of said complex to bind or activate an E2F DNA binding site in vitro.

10. The screening assay of claim 8 wherein the putative inhibitor is a fragment of 10 or more amino acids of the polypeptide of claim 2.

11. An assay according to claim 8 which further comprises selecting as an inhibitor of E2F-5/DP complex formation a compound capable of so disrupting said complex formation.

WEST

Generate Collection Print

appl # 09/309,935 different SEQ ID protein

L3: Entry 6 of 12 File: USPT Jul 31, 2001

US-PAT-NO: 6268334
DOCUMENT-IDENTIFIER: US 6268334 B1

TITLE: Peptide antagonists of DP transcription factors

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
La Thangue; Nicholas B.	Glasgow			GB
Bandara; Lasantha R.	Abingdon			GB

US-CL-CURRENT: 514/2; 530/300

CLAIMS:

What is claimed is:

1. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F.

2. The stent of claim 1 wherein said variant includes a substitution selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.

3. The stent of claim 1 wherein said variant consists of the amino acid sequence of SEQ ID NO: 15.

4. The stent of claim 1 wherein said variant consists of the amino acid sequence of SEQ ID NO: 16.

5. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F heterodimer, wherein said polypeptide is fused at its N- or C-terminus to a membrane translocation sequence.

6. The stent of claim 5 wherein said membrane translocation sequence is derived from the Drosophila melanogaster antennapedia protein.

7. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3 and, from 0 to 5 amino acids at the N- or C-terminus, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F heterodimer.

8. The stent of claim 7, wherein said variant includes a substitution selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.

9. The stent of claim 7, wherein said variant consists of the amino acid sequence of SEQ ID NO: 15.

10. The stent of claim 7, wherein said variant consists of the amino acid sequence of SEQ ID NO: 16.

US-PAT-NO: 5863757

DOCUMENT-IDENTIFIER: US 5863757 A

TITLE: Transcription factor DP-1

DATE-ISSUED: January 26, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
La Thangue; Nicholas Barrie	London	N/A	N/A	GB

US-CL-CURRENT: 435/69.1, 435/320.1 , 435/325 , 536/23.5 , 536/24.31

CLAIMS:

I claim:

1. An isolated polynucleotide which comprises the sequence of SEQ ID NO:1 or its complement.

2. The polynucleotide of claim 1 which is a DNA polynucleotide.

3. A double stranded polynucleotide comprising a polynucleotide according to claim 1 and its complement.

4. A replicable vector which comprises a polynucleotide according to claim 1.

5. A host cell comprising a vector according to claim 4.

6. An isolated polynucleotide which comprises a fragment of at least 15 nucleotides of the polynucleotide of SEQ ID NO:1 or its complement.

7. The isolated polynucleotide of claim 6 which comprises at least 40
nucleotides of the polynucleotide of SEQ ID NO:1 or its complement.

8. The isolated polynucleotide of claim 6 which comprises the open reading
frame of SEQ ID NO:1.

9. The isolated polynucleotide of claim 8 which is a DNA polynucleotide.

10. A replicable vector which comprises a polynucleotide according to claim
8.

11. A host cell comprising a vector according to claim 10.

12. An isolated polynucleotide which comprises a contiguous sequence of
nucleotides having at least 80% homology to at least 40 contiguous nucleotides
of SEQ ID NO:1.

13. The isolated polynucleotide of claim 12 which encodes the polypeptide
as set out in SEQ ID NO:2.

14. The isolated polynucleotide of claim 12 which encodes a peptide
sequence as set out as residues 160-220 of SEQ ID NO:2.

15. The isolated polynucleotide of claim 12 which is a DNA polynucleotide.

16. A replicable vector which comprises a polynucleotide according to claim
12.

17. A host cell comprising a vector according to claim 12.

18. An expression vector which comprises polynucleotide having an open
reading frame operably linked to a promoter, said open reading frame encoding a
polypeptide selected from the group consisting of:

(a) the polypeptide of SEQ ID NO:2;

(b) an allelic variant or mammalian homologue of SEQ ID NO:2;

(c) a polypeptide having at least 70% homology over at least 20 amino acids
to SEQ ID NO:2;

(d) a fragment of any one of (a) to (c) capable of forming a complex with
the E2F-1 protein; and

(e) a fragment of any one of (a) to (c) of at least 15 amino acids.

19. A host cell transformed by the expression vector of claim 18.

20. A process for preparing a polypeptide encoded by the expression vector
of claim 18 which process comprises cultivating a host cell transformed by said
expression vector under conditions to provide for expression by said vector of
the open reading frame, and recovering the expressed polypeptide.

US-PAT-NO: 6268334 Not double patenting

DOCUMENT-IDENTIFIER: US 6268334 B1

TITLE: Peptide antagonists of DP transcription factors

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
La Thangue; Nicholas B.	Glasgow	N/A	N/A	GB
Bandara; Lasantha R.	Abingdon	N/A	N/A	GB

US-CL-CURRENT: 514/2, 530/300

CLAIMS:

What is claimed is:

1. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F.

2. The stent of claim 1 wherein said variant includes a substitution selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.

3. The stent of claim 1 wherein said variant consists of the amino acid sequence of SEQ ID NO: 15.

4. The stent of claim 1 wherein said variant consists of the amino acid sequence of SEQ ID NO: 16.

5. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F heterodimer, wherein said polypeptide is fused at its N- or C-terminus to a membrane translocation sequence.

6. The stent of claim 5 wherein said membrane translocation sequence is derived from the Drosophila melanogaster antennapedia protein.

7. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3 and, from 0 to 5 amino acids at the N- or C-terminus, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F heterodimer.

8. The stent of claim 7, wherein said variant includes a substitution selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.

9. The stent of claim 7, wherein said variant consists of the amino acid sequence of SEQ ID NO: 15.

10. The stent of claim 7, wherein said variant consists of the amino acid sequence of SEQ ID NO: 16.

09/900,147

NCBI PubMed National Library of Medicine NLM

PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM B

Search PubMed for Preview Go Clea

Limits Preview/Index **History** Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutoriai
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Browser
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

- Search History will be lost after one hour of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Search	Most Recent Queries	Time	Result
#13	Related Articles for PubMed (Select 8989145)	14:12:06	122
#11	Search circulation[jour] AND 94[volume] AND 3311[page] Field: Title Word	14:10:40	1
#9	Related Articles for PubMed (Select 10922232)	13:26:04	155
#5	Related Articles for PubMed (Select 9440847)	13:09:49	184
#3	Search j endourol[jour] AND 11[volume] AND 399[page] Field: Title Word	13:06:11	1
#1	Search stent AND peptides	13:03:49	164

Clear History

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

i686-pc-linux-gnu Dec 13 2002 14:22:59

09/900,167

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
E2F	359
E2FS	14
PROTEIN	116330
PROTEINS	94589
@PD	7087668
((2 AND (E2F ADJ PROTEIN)) AND ((@PD > "20021216")!)).USPT.	0
((L2 AND E2F PROTEIN) AND ((@PD > 20021216)!)).USPT.	0

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L3

Refine Search

Recall Text | Clear

Search History

DATE: Monday, June 09, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L3	(L2 and e2f protein) AnD ((@pd > 20021216)!)	0	L3
L2	(dp protein) AnD ((@pd > 20021216)!)	2	L2
L1	(dp-1) AnD ((@pd > 20021216)!)	6	L1

END OF SEARCH HISTORY